Clatacef Use In Pregnancy & Lactation

Pregnancy: Pregnancy Category B.
Reproduction studies have been performed in pregnant mice given cefotaxime IV at dosages up to 1,200 mg/kg/day (0.4 times the recommended human dosage based on mg/m²) or in pregnant rats when administered IV at dosages up to 1,200 mg/kg/day (0.8 times the recommended human dosage based on mg/m²). No evidence of embryotoxicity or teratogenicity was seen in these studies.
There are no well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, use this drug during pregnancy only if clearly needed. Use of the drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible risks. In perinatal and postnatal studies with rats, the pups in the group given 1,200 mg/kg of cefotaxime were significantly lighter in weight at birth and remained smaller than pups in the control group during the 21 days of breast-feeding.
Lactation: Cefotaxime is excreted in human milk in low concentrations. Exercise caution when cefotaxime is administered to a breast-feeding woman.